Neuroprotection in an Experimental Model of Multiple Sclerosis via Opening of Big Conductance, Calcium-Activated Potassium Channels.

BK channel autoimmunity experimental autoimmune encephalomyelitis multiple sclerosis neuroprotection

Journal

Pharmaceuticals (Basel, Switzerland)
ISSN: 1424-8247
Titre abrégé: Pharmaceuticals (Basel)
Pays: Switzerland
ID NLM: 101238453

Informations de publication

Date de publication:
07 Jul 2023
Historique:
received: 23 05 2023
revised: 02 07 2023
accepted: 05 07 2023
medline: 29 7 2023
pubmed: 29 7 2023
entrez: 29 7 2023
Statut: epublish

Résumé

Big conductance calcium-activated (BK) channel openers can inhibit pathologically driven neural hyperactivity to control symptoms via hyperpolarizing signals to limit neural excitability. We hypothesized that BK channel openers would be neuroprotective during neuroinflammatory, autoimmune disease. The neurodegenerative disease was induced in a mouse experimental autoimmune encephalomyelitis model with translational value to detect neuroprotection in multiple sclerosis. Following the treatment with the BK channel openers, BMS-204253 and VSN16R, neuroprotection was assessed using subjective and objective clinical outcomes and by quantitating spinal nerve content. Treatment with BMS-204253 and VSN16R did not inhibit the development of relapsing autoimmunity, consistent with minimal channel expression via immune cells, nor did it change leukocyte levels in rodents or humans. However, it inhibited the accumulation of nerve loss and disability as a consequence of autoimmunity. Therefore, in addition to symptom control, BK channel openers have the potential to save nerves from excitotoxic damage and could be useful as either stand-alone neuroprotective agents or as add-ons to current disease-modifying treatments that block relapsing MS but do not have any direct neuroprotective activity.

Identifiants

pubmed: 37513884
pii: ph16070972
doi: 10.3390/ph16070972
pmc: PMC10383993
pii:
doi:

Types de publication

Journal Article

Langues

eng

Subventions

Organisme : FastForward at the National Multiple Sclerosis Society
ID : FF-1602-07939
Organisme : Fight for Sight
ID : 1858/1859
Organisme : The Wellcome Trust
ID : 206020/Z/16/Z
Organisme : the Technology Strategy Board/Innovate UK
ID : 25036-166159

Références

J Neurosci. 2014 Sep 3;34(36):11929-47
pubmed: 25186741
Acta Neurobiol Exp (Wars). 2016;76(1):20-31
pubmed: 27102915
Brain. 2013 Apr;136(Pt 4):1067-82
pubmed: 23518709
Rev Neurosci. 2013;24(1):71-88
pubmed: 23152401
Neurobiol Dis. 2013 Jul;55:87-94
pubmed: 23567653
Lancet Neurol. 2010 Jul;9(7):681-8
pubmed: 20621711
Nat Commun. 2015 Oct 06;6:8518
pubmed: 26439639
Invest Ophthalmol Vis Sci. 2020 Mar 9;61(3):41
pubmed: 32203982
Brain. 2022 Mar 29;145(1):76-82
pubmed: 34196695
Exp Neurol. 2012 Dec;238(2):149-55
pubmed: 22960185
Proteomics. 2007 Aug;7(15):2591-602
pubmed: 17610306
J Neuroimmunol. 1993 Jun;45(1-2):1-14
pubmed: 8331154
J Neurochem. 2003 Jan;84(2):325-35
pubmed: 12558995
Cochrane Database Syst Rev. 2003;(4):CD001332
pubmed: 14583932
Acta Neuropathol Commun. 2013 Dec 23;1:84
pubmed: 24364862
PLoS One. 2013 Aug 01;8(8):e70019
pubmed: 23936370
Eur J Neurol. 2019 Jan;26(1):27-40
pubmed: 30300457
Science. 2015 Jan 23;347(6220):1260419
pubmed: 25613900
Ann Neurol. 2003 Feb;53(2):174-80
pubmed: 12557283
PLoS One. 2022 Sep 14;17(9):e0274565
pubmed: 36103562
Biophys J. 2008 May 1;94(9):3706-13
pubmed: 18199674
Eur J Immunol. 2005 Apr;35(4):1027-36
pubmed: 15770697
BMC Genomics. 2013 Sep 20;14:632
pubmed: 24053356
Eur J Pharmacol. 2017 Jun 15;805:14-24
pubmed: 28327344
Genome Biol. 2009;10(11):R130
pubmed: 19919682
Clin Exp Immunol. 1992 Oct;90(1):124-8
pubmed: 1395092
Brain. 2014 Jan;137(Pt 1):92-108
pubmed: 24287115
Acta Neurol Scand. 2022 Dec;146(6):699-707
pubmed: 36225112
Nat Med. 2001 Apr;7(4):471-7
pubmed: 11283675
Mult Scler Relat Disord. 2012 Jan;1(1):29-38
pubmed: 25876448
Mol Cell Proteomics. 2005 Dec;4(12):1920-32
pubmed: 16127175
J Immunol. 2012 Jun 15;188(12):5877-86
pubmed: 22581856
Chem Phys Lipids. 2017 Oct;207(Pt B):135-150
pubmed: 28322741
J Cereb Blood Flow Metab. 2001 Apr;21(4):396-403
pubmed: 11323525
Front Physiol. 2014 Sep 29;5:373
pubmed: 25324781
Proc Natl Acad Sci U S A. 2004 Apr 20;101(16):6062-7
pubmed: 15075390
Curr Med Chem. 2008;15(11):1126-46
pubmed: 18473808
Cephalalgia. 2015 Jan;35(1):16-35
pubmed: 24820887
Acta Neuropathol Commun. 2023 May 22;11(1):84
pubmed: 37217978
Lancet Neurol. 2013 Sep;12(9):857-865
pubmed: 23856559
Oxid Med Cell Longev. 2022 Nov 23;2022:2257427
pubmed: 36466093
Neurosci Lett. 2011 Jan 20;488(2):178-82
pubmed: 21087654
Am J Physiol Cell Physiol. 2011 Jun;300(6):C1393-403
pubmed: 21325638
Brain Dev. 2017 Jun;39(6):464-469
pubmed: 28202262
Pharmacol Res. 2014 Sep;87:80-6
pubmed: 24973659
Lancet Neurol. 2016 Mar;15(3):259-69
pubmed: 26822749
F1000Res. 2021 Aug 9;10:781
pubmed: 34909188
Sci Immunol. 2021 Feb 12;6(56):
pubmed: 33579751
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5562-7
pubmed: 10792058
Molecules. 2022 Jul 18;27(14):
pubmed: 35889443
Eur J Clin Pharmacol. 2017 Jul;73(7):811-817
pubmed: 28378057
Orphanet J Rare Dis. 2014 Aug 01;9:124
pubmed: 25079250
CNS Drug Rev. 2002 Winter;8(4):353-60
pubmed: 12481191
Ann Clin Transl Neurol. 2021 Dec;8(12):2235-2251
pubmed: 34792863
Br J Pharmacol. 2017 Aug;174(16):2662-2681
pubmed: 28677901
J Biol Chem. 2016 Feb 26;291(9):4356-73
pubmed: 26679998
Br J Pharmacol. 2007 Nov;152(5):751-64
pubmed: 17891160
Immunome Res. 2008 Apr 29;4:5
pubmed: 18442421

Auteurs

Gareth Pryce (G)

BartsMS, The Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.

Sofia Sisay (S)

BartsMS, The Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.

Gavin Giovannoni (G)

BartsMS, The Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.

David L Selwood (DL)

Wolfson Institute for Biomedical Research, University College London, London WC1E 6BT, UK.

David Baker (D)

BartsMS, The Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London, London E1 2AT, UK.

Classifications MeSH